Stock Track | Celcuity Soars 7.24% on Better-Than-Expected Q3 Earnings

Stock Track

Nov 13

Celcuity Inc. (CELC) shares surged 7.24% in intraday trading on Wednesday after the company reported better-than-expected third-quarter earnings results. The biotechnology firm, which focuses on developing targeted therapies for cancer patients, demonstrated strong financial performance despite ongoing research and development expenses.

According to the company's latest financial report, Celcuity posted an adjusted earnings per share (EPS) of -$0.78 for the third quarter, significantly outperforming the consensus estimate of -$1.02 provided by IBES. This represents a positive surprise and suggests that the company is managing its finances more effectively than analysts had anticipated.

While Celcuity reported a net loss of $43.8 million for the quarter, investors appeared to focus on the company's ability to control costs and exceed earnings expectations. Operating expenses for the period stood at $42.8 million, reflecting the company's continued investment in its drug development pipeline. The market's positive reaction indicates confidence in Celcuity's strategic direction and potential for future growth in the competitive oncology sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1147621465"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147621465\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147621465?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147621465","market":"nz","top_or_hot":-1,"title":"Stock Track | Celcuity Soars 7.24% on Better-Than-Expected Q3 Earnings","media":"Stock Track","content":"<p>Celcuity Inc. (CELC) shares surged 7.24% in intraday trading on Wednesday after the company reported better-than-expected third-quarter earnings results. The biotechnology firm, which focuses on developing targeted therapies for cancer patients, demonstrated strong financial performance despite ongoing research and development expenses.</p>\n\n<p>According to the company's latest financial report, Celcuity posted an adjusted earnings per share (EPS) of -$0.78 for the third quarter, significantly outperforming the consensus estimate of -$1.02 provided by IBES. This represents a positive surprise and suggests that the company is managing its finances more effectively than analysts had anticipated.</p>\n\n<p>While Celcuity reported a net loss of $43.8 million for the quarter, investors appeared to focus on the company's ability to control costs and exceed earnings expectations. Operating expenses for the period stood at $42.8 million, reflecting the company's continued investment in its drug development pipeline. The market's positive reaction indicates confidence in Celcuity's strategic direction and potential for future growth in the competitive oncology sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Celcuity Soars 7.24% on Better-Than-Expected Q3 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Celcuity Soars 7.24% on Better-Than-Expected Q3 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-13 05:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Celcuity Inc. (CELC) shares surged 7.24% in intraday trading on Wednesday after the company reported better-than-expected third-quarter earnings results. The biotechnology firm, which focuses on developing targeted therapies for cancer patients, demonstrated strong financial performance despite ongoing research and development expenses.</p>\n\n<p>According to the company's latest financial report, Celcuity posted an adjusted earnings per share (EPS) of -$0.78 for the third quarter, significantly outperforming the consensus estimate of -$1.02 provided by IBES. This represents a positive surprise and suggests that the company is managing its finances more effectively than analysts had anticipated.</p>\n\n<p>While Celcuity reported a net loss of $43.8 million for the quarter, investors appeared to focus on the company's ability to control costs and exceed earnings expectations. Operating expenses for the period stood at $42.8 million, reflecting the company's continued investment in its drug development pipeline. The market's positive reaction indicates confidence in Celcuity's strategic direction and potential for future growth in the competitive oncology sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CELC","symbol_name":"Celcuity Inc","start_time":0,"source_url":"","article_id":"1147621465","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147621465","pubTimestamp":1762981343,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Celcuity Inc. (CELC) shares surged 7.24% in intraday trading on Wednesday after the company reported better-than-expected third-quarter earnings results. The biotechnology firm, which focuses on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CELC":"Celcuity Inc"},"translate_title":"个股追踪|Celcuity大涨7.24%Q3盈利好于预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":1},"content_text":"Celcuity Inc. (CELC) shares surged 7.24% in intraday trading on Wednesday after the company reported better-than-expected third-quarter earnings results. The biotechnology firm, which focuses on developing targeted therapies for cancer patients, demonstrated strong financial performance despite ongoing research and development expenses.\nAccording to the company's latest financial report, Celcuity posted an adjusted earnings per share (EPS) of -$0.78 for the third quarter, significantly outperforming the consensus estimate of -$1.02 provided by IBES. This represents a positive surprise and suggests that the company is managing its finances more effectively than analysts had anticipated.\nWhile Celcuity reported a net loss of $43.8 million for the quarter, investors appeared to focus on the company's ability to control costs and exceed earnings expectations. Operating expenses for the period stood at $42.8 million, reflecting the company's continued investment in its drug development pipeline. The market's positive reaction indicates confidence in Celcuity's strategic direction and potential for future growth in the competitive oncology sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}